Related references
Note: Only part of the references are listed.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades
Tao Lu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index
Yun Yang et al.
BIOTECHNOLOGY LETTERS (2018)
CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises
Bing Tong et al.
FUTURE ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeted next generation sequencing identified a high frequency genetic mutated profile in wood smoke exposure-related lung adenocarcinoma patients
Giovanny Soca-Chafre et al.
Oncotarget (2018)
Prognostic significance of CD47 in human malignancies: a systematic review and meta-analysis
Hui-Jun Zhao et al.
TRANSLATIONAL CANCER RESEARCH (2018)
Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage. a non-small cell lung cancer.
Yan Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Ken Uchibori et al.
NATURE COMMUNICATIONS (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen K. Horrigan
ELIFE (2017)
Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells
Liang Liu et al.
FRONTIERS IN IMMUNOLOGY (2017)
CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients
Lourdes Barrera et al.
BRITISH JOURNAL OF CANCER (2017)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
Sukhbir Kaur et al.
ONCOTARGET (2016)
N-Glycosylation of integrin α5 acts as a switch for EGFR-mediated complex formation of integrin α5β1 to α6β4
Qinglei Hang et al.
SCIENTIFIC REPORTS (2016)
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
Tetsuro Sasada et al.
FRONTIERS IN PHARMACOLOGY (2016)
CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer
Hui Zhao et al.
SCIENTIFIC REPORTS (2016)
Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure
Alette Ortega-Gomez et al.
RESPIRATORY RESEARCH (2016)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
K. Azuma et al.
ANNALS OF ONCOLOGY (2014)
Adverse effects of wood smoke PM2.5 exposure on macrophage functions
Christopher T. Migliaccio et al.
INHALATION TOXICOLOGY (2013)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
Mark P. Chao et al.
BLOOD (2011)
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
Kenneth J. O'Byrne et al.
LANCET ONCOLOGY (2011)
Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47
Sukhbir Kaur et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
